Advances have been made in the discovery of biomarkers for glomerular diseases, including the discovery of the M-type phospholipase A2 receptor, thrombospondin type-1 domain-containing 7A, neural epidermal growth factor-like 1 protein and others as target antigens in many patients with membranous GN [40, 41] or galactose-deficient IgA1 and antiglycan response in IgA nephropathy [42]. This evidence concerns the gene NELL1 and idiopathic membranous glomerulonephritis.